TH and metabolic dysfunction-associated steatohepatitis: In this scenario, the recent approval of resmetirom, a selective THR-β agonist, for the treatment of nonalcoholic steatohepatitis is an example of how we can benefit from manipulating TH signaling specifically in some tissues without exposing patients to systemic dysthyroidism (35).